cornellcutbacks

Two revitalized studies from the Clinical Antipsychotic Trials instead of Intervention Effectiveness (CATIE) provide more insights into comparing treatment options, and to what extent antipsychotic medications facilitate people with schizophrenia learn social, interpersonal and community living skills. The reborn studies are published in the March 2007 issue of the American Journal of Psychiatry. CATIE, a $42.6 million, multi-site ruminate on, was funded by the National Institutes of Health’s National Start of Mental Form (NIMH).

Comparing Newer Antipsychotic Medications After Older Identical Fails

Quetiapine, and to some extent olanzapine, may be more possessions than risperidone volume patients who were originally taking, but had to discontinue, perphenazine - an older, premier generation antipsychotic medication. But, patient responses varied considerably.

“CATIE continues to fine-pay attention to our brainpower of how our arsenal of antipsychotic medications mix in tangible-set settings, but it also is revealing to us what questions we still requirement address,” said NIMH Director Thomas R. Insel, M.D.

Of the 257 patients who were initially randomized to perphenazine in the CATIE study, 192 discontinued the medication in the direction of a number of reasons, including ineffectiveness and intolerable side effects. Among those who discontinued, 114 agreed to be re-randomized to one of three newer antipsychotic medications - olanzapine, quetiapine or risperidone.

T. Scott Stroup, M.D., MPH, of the University of North Carolina at Chapel Hill, and colleagues compared the effectiveness of the medications by determining how crave patients stayed on their assigned medication. Those taking quetiapine stayed on the longest - averaging there ten months before discontinuing. Those taking olanzapine discontinued after an average of about seven months, and those taking risperidone discontinued after an for the most part of four months.

Although the discontinuation results suggest that olanzapine was generally on par with quetiapine, patients entrancing olanzapine accomplished more side effects. While not any of those taking quetiapine discontinued use due to weight gain or metabolic side effects, 13 percent of those assigned to olanzapine discontinued it payable to weight gain or metabolic problems, and 5 percent of those on risperidone did so.

“These results fortify the fact that finding the most striking medication in return each patient sometimes means distressing multiple medications,” said Dr. Stroup. “They cue us of the worthy variability in clinical circumstances and of our need to be responsive to an individual’s needs and preferences.”

Schizophrenia Patients’ Social and Community Living Skills Improve Modestly While on Antipsychotic Medications

Patients with schizophrenia taking antipsychotic medications experience modest improvements in communal, interpersonal and community living (psychosocial) skills, regardless of what antipsychotic medication they are taking.

Improvements in psychosocial skills among patients with schizophrenia have been notoriously onerous to achieve, even when the more disruptive symptoms of the affliction can be controlled. “Helping patients with schizophrenia restore their psychosocial functioning remains a challenge,” said NIMH Director Thomas R. Insel, M.D. “These CATIE results support the growing understanding that we must do a better responsibility of helping patients get their sustenance skills back on rails.”

Marvin Swartz, M.D., of Duke University and colleagues evaluated the sexually transmitted and vocational functioning, interpersonal relationships, and psychological well-being of 455 participants - helter-skelter one-third of all patients in the CATIE study - who completed an initial appraisal earlier the study began and were available to forearm data after 12 months of treatment. In the first phase of the CATIE muse about, patients were randomly assigned to take either perphenazine - an older, first-period antipsychotic medication - or one of several newer, second-crop medications (olanzapine, quetiapine, risperidone, or ziprasidone).

The researchers develop that those patients who stuck with their initial treatment showed some improvement in their psychosocial functioning, and there were no differences number the medications in making these gains. The results are consistent with hitherto reported CATIE results (http://www.nimh.nih.gov/healthinformation/catie.cfm) in which few differences were seen among perphenazine and the newer, second-generation antipsychotic medications in effectively reducing symptoms.

The patients who made the greatest gains were the ones with the poorest community living skills at the inception of the look at, but they were also more tenable to discontinue treatment early in the process. As illustrious in premature CATIE reports, varied patients discontinued their initial treatments because of intolerable side effects or ineffectiveness.

“Over the long go on the lam patients are more likely to purpose better in the community if they are able to stay on their monogram treatment, especially those who are the most impaired,” said Dr. Swartz. “More intensive rehabilitative interventions and outreach may help patients stick with their treatment and make greater gains.”

Patients who made few gains in community living skills were those with higher-status psychosocial skills at the beginning of the study. Swartz and colleagues posit that patients encountered a “ceiling effect” at which point additional psychosocial skill recuperation was unlikely without additional rehabilitative treatment.

“Overall, the findings rehash the widely held maxim that antipsychotic medications alone are not enough in helping patients lunge at telling gains in intrinsic-world functioning,” said Dr. Swartz. “Dedicated rehabilitative services that help patients learn to function at work and in common settings are sorely needed.”

—————————-
Article adapted by Medical Talk Today from earliest press let off.
—————————-

CONTACT:
Mary Partlow
NIMH Press Office

The National Institute of Mental Health (NIMH) legation is to diminish the burden of temperament and behavioral disorders through research on mind, genius, and behavior. More information is available at the NIMH website, http://www.nimh.nih.gov/.

The Chauvinistic Institutes of Health (NIH) - The Nation’s Medical Examine Mechanism - includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Vulnerable Services. It is the primary federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both unexceptional and rare diseases. For more information in the air NIH and its programs, stay http://www.nih.gov/.

Stroup TS, et al. Effectiveness of Olanzapine, Quetiapine and Risperidone in Patients with Long-lived Schizophrenia After Discontinuing Perphenazine: A CATIE Study. American Journal of Psychiatry 2007; 164:3.

Swartz MS, et al. Effects of Antipsychotic Medications on Psychosocial Functioning in Patients with Chronic Schizophrenia: Findings From the NIMH CATIE Over. American Diary of Psychiatry 2007; 164:3.

Contact: Colleen Labbe

NIH/National Institute of Mental Salubrity